Projects per year
Associate Dean for Postgraduate Research, Faculty of Science (2019 - present)
Director of the Biomedical Research Centre, UEA (2015 - present)
As an early career scientist I trained in the laboratories of Professor David Beech FMedSci (Leeds) and Professor R. Alan North FRS (Manchester), and established an independent research group following the award of a prestigious BBSRC David Phillips Fellowship. We collaborate with clinicians at the Norfolk & Norwich University Hospital, partners in Pharmaceutical industry and other academic groups to tackle pressing and challenging projects. My expertise encompass pharmacological and physiological aspects of vascular and adipose tissues, and the biophysical and pharmacological properties of ligand- and voltgae-gated ion channels.
- Senior Lecturer in Pharmacology, University of East Anglia (2015 - present)
- Lecturer in Pharmacology, University of East Anglia (2013 - 2015)
- BBSRC David Phillips Fellow, University of East Anglia (2010 – 2013)
- BBSRC David Phillips Fellow, University of Leeds (2008 – 2010)
- Wellcome Trust Research Associate, University of Manchester (2004 – 2008)
- MRC-funded PhD, University of Leeds (2000 – 2004)
- BSc (Hons) Pharmacology, University of Leeds (1997 – 2000)
Key Research Interests and Expertise
Our overarching research interest is the role ion channels and receptors play in the cellular and molecular mechanisms that underlie cardiometabolic physiology and disease with an emphasis of blood vessels, adipose tissue and the peripheral nervous system.
Vascular pharmacology & physiology We are interested in the role of the peripheral nervous system in controlling human arterial and venous blood flow, in additional to the role of vascular endothelium in the mechanical detection of blood flow.
Adipose biology and dysfunction We are interested in the role of efferent and afferent nervous innervation of human white adipose tissue and regulatory changes associated with metabolic disease.
Receptor-ligand interactions and drug discovery We have an active programme to investigate novel molecules that allosterically modulate human P2X receptors (a family of ligand-gated ion channels). We are interested in the identification (via HTS) and molecular interaction of (in silico docking, receptor-ligand SAR) small molecules, natural products and antibodies with human P2X receptors.
Our research programme is generously funded by the British Heart Foundation, BBSRC, Merck and AstraZeneca.
Major experimental techniques available in the lab
Pressure myography using human and animal arteries
Wire myography using human and animal arteries
Single-cell calcium imaging
Manual patch-clamp electrophysiology
Planar patch-clamp electrophysiology
Extracellular neurophysiological recordings
High throughput compound screens (Flexstation)
Research Group Membership
Samuel J. Fountain BSc PhD FHEA (Principal Investigator)
Dr Maria del Carmen Gonzalez-Montelongo (BHF funded Senior Research Associate)
Dr Neville Ngum (BHF funded Senior Research Associate)
Dr Stefan Bidula (BHF funded Senior Research Associate)
Postgraduate Research Students
Michelle Fletcher (BBSRC iCASE with AstraZeneca) (2019 - 2023)
Sonia Paz BSc (BBSRC DTP Studentship) (2019 - 2023)
Jessica Meades BSc (BBSRC iCASE Studentship with Merck, USA) (2018 - 2022)
Anna Fortuny Gomez BSc (BBSRC DTP Studentship) (2018 - 2022)
Dalyan Eldaly (Article 26 studentship) (2018 - 2021)
Masters by Research
Sean Cullum BSc
Harry Hickey BSc
- Editor Purinergic Signalling (2013 - present)
- Physiological Society (London) Mentor (2002 - present)
- British Pharmacological Society (2005 - present)
2016, Afferent Pharmaceuticals
Dive into details
Select a country/territory to view shared publications and projects
1/01/20 → 31/12/22
1/10/19 → 30/09/23
1/10/18 → 30/03/22
Neuropeptide Y facilitates P2X1 receptor-dependent vasoconstriction via Y1 receptor activation in small mesenteric arteries during sympathetic neurogenic responsesGonzalez-Montelongo, M. & Fountain, S. J., Feb 2021, In : Vascular Pharmacology. 136, 106810.
Research output: Contribution to journal › Article1 Citation (Scopus)
Taspine is a natural product that suppresses P2X4 receptor activity via phosphoinositide 3‐kinase inhibitionNadzirin, I. B., Fortuny‐Gomez, A., Ngum, N., Richards, D., Ali, S., Searcey, M. & Fountain, S. J., 16 Aug 2021, In : British Journal of Pharmacology.
Research output: Contribution to journal › Article
Fountain, S. J., Kennedy, C., Schmalzing, G., Jarvis, M. F., Stojilkovic, S. S., King, B. F. & Di Virgilio, F., Feb 2021, In : British Journal of Pharmacology. 178, 3, p. 489-514 26 p.
Research output: Contribution to journal › Review articleOpen AccessFile23 Citations (Scopus)5 Downloads (Pure)
SUN1/2 Are Essential for RhoA/ROCK-Regulated Actomyosin Activity in Isolated Vascular Smooth Muscle CellsPorter, S., Minaisah, R. M., Ahmed, S., Ali, S., Norton, R., Zhang, Q., Ferraro, E., Molenaar, C., Holt, M., Cox, S., Fountain, S., Shanahan, C. & Warren, D., 6 Jan 2020, In : Cells. 9, 1, 17 p., 132.
Research output: Contribution to journal › ArticleOpen AccessFile2 Citations (Scopus)44 Downloads (Pure)
Action of MK‐7264 (Gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisationRichards, D., Gever, J. R., Ford, A. P. & Fountain, S., Jul 2019, In : British Journal of Pharmacology. 176, 13, p. 2279-2291 13 p.
Research output: Contribution to journal › ArticleOpen AccessFile20 Citations (Scopus)53 Downloads (Pure)